Comparison of echocardiographic parameters in Fabry cardiomyopathy and light-chain cardiac amyloidosis

被引:5
|
作者
Marek, Josef [1 ,2 ]
Palecek, Tomas [1 ,2 ]
Magne, Julien [3 ]
Lavergne, David [4 ]
Boulogne, Cyrille [3 ]
Fadel, Bahaa M. [5 ]
Jaccard, Arnaud [4 ]
Linhart, Ales [1 ,2 ]
Mohty, Dania [3 ,5 ]
机构
[1] Charles Univ Prague, Dept Med 2, Dept Cardiovasc Med, Fac Med 1, Prague, Czech Republic
[2] Gen Univ Hosp Prague, Prague, Czech Republic
[3] Dupuytren Univ Hosp, Dept Cardiol, Limoges, France
[4] Dupuytren Univ Hosp, Natl Reference Ctr Light Chain Syst Amyloidosis, Dept Hematol, Limoges, France
[5] King Faisal Specialist Hosp & Res Ctr, Heart Ctr, Sect Adult Cardiol, Riyadh, Saudi Arabia
关键词
diastolic function; echocardiography; Fabry disease; restrictive cardiomyopathy; systolic function; VENTRICULAR DIASTOLIC FUNCTION; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; DOPPLER-ECHOCARDIOGRAPHY; REPLACEMENT THERAPY; ENZYME REPLACEMENT; DISEASE; AL; HYPERTENSION; DYSFUNCTION;
D O I
10.1111/echo.14144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Aims Fabry cardiomyopathy (FC) and light-chain amyloid cardiomyopathy (AL) present with concentric left ventricular (LV) hypertrophy/remodeling and diastolic rather than systolic dysfunction. Direct comparisons are difficult due to rarity and confounded by variability of LV thickness. To compare LV diastolic and systolic properties between patients with FC and AL in a cohort matched for interventricular septal thickness (IVS). Methods Results A two-center echocardiographic analysis was performed, comprising 118 patients with IVS >= 12 mm (FC and AL 59 patients each) matched by IVS. Fabry cardiomyopathy patients had larger LV end-diastolic diameter (47.7 [44.0-50.9] vs 45.0 [41.5-49.0] mm, P = 0.002), better LV ejection fraction (EF 68.7 [63.4-74.0] vs 63.0 [54.0-70.0]%, P = 0.001) and midwall fractional shortening (midFS 14.8 [13.0-16.1] vs 12.1 [8.9-15.0]%, P = 0.006). LV EF <40% was rare in both (2% vs 7%, P = 0.17). AL patients expressed higher LV diastolic dysfunction grade (III in 26% vs 4%, II in 21% vs 12% and I in 54% vs 84%, P = 0.004), with higher E/e' ratio (13.6 [10.2-18.8] vs 9.8 [7.5-12.3], P < 0.0001). Average E/e' ratio and midFS were significantly associated with NYHA severity in both groups (P < 0.05 for all). Conclusions Matched AL patients had worse LV diastolic function than FC, driven by E/e'. Significant LV systolic dysfunction was rare overall. MidFS and E/e' were associated with heart failure severity in both groups.
引用
收藏
页码:1755 / 1763
页数:9
相关论文
共 50 条
  • [1] Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy
    Dinwoodey, Danya L.
    Skinner, Martha
    Maron, Martin S.
    Davidoff, Ravin
    Ruberg, Frederick L.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (05): : 674 - 676
  • [2] Light-chain cardiac amyloidosis
    Mankad, Anit K.
    Sesay, Isata
    Shah, Keyur B.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 144 - 156
  • [3] Clinical and Echocardiographic Correlates of Elevated Troponin in Amyloid Light-Chain Cardiac Amyloidosis
    Apridonidze, Teimuraz
    Steingart, Richard M.
    Comenzo, Raymond L.
    Hoffman, James
    Goldsmith, Yuliya
    Bella, Jonathan N.
    Landau, Heather
    Liu, Jennifer E.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (08): : 1180 - 1184
  • [4] CARDIAC AMYLOIDOSIS AND LIGHT-CHAIN MYELOMA
    MUNARRIZ, B
    MOLINS, C
    BALLESTER, M
    RAMOS, V
    [J]. REVISTA CLINICA ESPANOLA, 1994, 194 (09): : 730 - 730
  • [5] Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy
    Yoshita, Mitsuhiro
    Ishida, Chiho
    Yanase, Daisuke
    Yamada, Masahito
    [J]. INTERNAL MEDICINE, 2006, 45 (03) : 159 - 162
  • [6] Clinical characteristics of patients with cardiac amyloidosis in Sarawak: Comparison between transthyretin and light-chain amyloid cardiomyopathy
    Chung, B. K.
    Leong, T. S.
    Chew, L. P.
    Law, W. C.
    Thien, L. K.
    Pang, I. X.
    Ling, H. S.
    Chow, H. B.
    Tan, C. T.
    Koh, K. T.
    Cham, Y. L.
    Said, A.
    Fong, A. Y. Y.
    Ong, T. K.
    Oon, Y. Y.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 369 : 20 - 20
  • [7] Echocardiographic phenotype and long-term prognosis in patients with light-chain cardiac amyloidosis
    Ntalianis, A.
    Tseliou, E.
    Repasos, E.
    Papadopoulou, E.
    Tselegkidi, M.
    Zografos, N.
    Ziogas, D.
    Koutsoukis, A.
    Maglaras, G.
    Stamoulopoulos, J.
    Koen, A.
    Dialoupi, I.
    Kastritis, E.
    Dimopoulos, M. A.
    Paraskevaidis, I.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 572 - 572
  • [8] Effects of treatment response on echocardiographic features among patients with light-chain cardiac amyloidosis
    Briasoulis, A.
    Rempakos, A.
    Petropoulos, I.
    Bampatsias, D.
    Theodorakakou, F.
    Dimopoulos, M. A.
    Stamatelopoulos, K.
    Kastritis, E.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [9] Light-chain cardiac amyloidosis: A multimodality approach
    Alexanderson-Rosas, Erick
    Escudero-Salamanca, Mara
    Garcia-Diaz, Jesus A.
    Alvarez-Santana, Ricardo
    Cano-Zarate, Roberto
    Mamani-Tito, Julio
    Carvajal-Juarez, Isabel
    Espinola-Zavaleta, Nilda
    [J]. JOURNAL OF NUCLEAR CARDIOLOGY, 2020, 27 (06) : 2432 - 2435
  • [10] Predictors of progression of light-chain cardiac amyloidosis
    Rameeva, A. S.
    Vedanova, K. V.
    Rameev, V. V.
    Safarova, A. F.
    Bobkova, I. N.
    Kozlovskaya, L. V.
    Moiseev, S. V.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 1237 - 1237